• FDA clears Iridex illumination probe for use with glaucoma laser

    Iridex has received FDA approval to commercialize its illumination probe for use in an advanced glaucoma procedure.
    March 16, 2017

    Iridex (Mountain View, CA) has received FDA approval to commercialize its G-Probe Illuminate probe, which offers combined transillumination and laser fiber for targeted transscleral cyclophotocoagulation (CPC; an advanced glaucoma procedure). The probe, which is powered by the company's Cyclo G6 glaucoma laser system, delivers transillumination to optimize its placement and, in turn, improve therapeutic outcomes.

    Related: Iridex ophthalmic laser system for glaucoma treatment receives CE Mark approval

    Studies have shown the ciliary body, the target tissue for a CPC treatment, naturally varies in location between patients, and cases of abnormal ocular size, high myopia, and post-corneal transplants generate even more challenges. The probe allows physicians to locate the ciliary body and deliver the laser treatment in a more targeted manner.

    The probe has utility in the operating room or as an outpatient, office-based procedure for treating glaucoma.

    For more information, please visit www.iridex.com.

    Sign up for Laser Focus World Newsletters
    Get the latest news and updates.

    Voice Your Opinion!

    To join the conversation, and become an exclusive member of Laser Focus World, create an account today!